Post-transplant Flotetuzumab for AML

NCT05506956 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Flotetuzumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]